Waldencast Reports Q3 2024 Financial Results
Portfolio Pulse from
Waldencast reported strong Q3 2024 financial results with $70.2 million in net revenue, marking a 34.6% growth compared to the previous year. Both Obagi Medical and Milk Makeup brands showed significant growth, and adjusted EBITDA increased by 134% from Q3 2023.
November 20, 2024 | 10:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Waldencast's Q3 2024 financial results show strong performance with a 34.6% increase in net revenue and a 134% rise in adjusted EBITDA compared to Q3 2023. Both Obagi Medical and Milk Makeup brands contributed significantly to this growth.
The significant growth in net revenue and adjusted EBITDA indicates strong operational performance and market demand for Waldencast's brands. This positive financial outcome is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100